Cargando…

Use of convalescent plasma in pregnant women with early stage COVID-19 infection in a tertiary care hospital in Dubai, February to March 2021: a case series study

BACKGROUND: The use of COVID-19 convalescent plasma (CCP) for the treatment of SARS-CoV-2 infection in pregnancy is intriguing in view of its safety profile in pregnancy and historical precedence of the use of plasma for other viral illnesses. This study aimed to evaluate the use of CCP in pregnant...

Descripción completa

Detalles Bibliográficos
Autores principales: Adan, Heba, Harb, Deemah, Hazari, Komal, Abdelkareem, Widad, Khan, Fareeda Nikhat, Zouaoui, Maryam, Raouf, May, Elsawy, Doaa, Azar, Aida Joseph, Khamis, Amar Hassan, Ammar, Abeer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509581/
https://www.ncbi.nlm.nih.gov/pubmed/36155102
http://dx.doi.org/10.1186/s12884-022-05043-w
_version_ 1784797256895954944
author Adan, Heba
Harb, Deemah
Hazari, Komal
Abdelkareem, Widad
Khan, Fareeda Nikhat
Zouaoui, Maryam
Raouf, May
Elsawy, Doaa
Azar, Aida Joseph
Khamis, Amar Hassan
Ammar, Abeer
author_facet Adan, Heba
Harb, Deemah
Hazari, Komal
Abdelkareem, Widad
Khan, Fareeda Nikhat
Zouaoui, Maryam
Raouf, May
Elsawy, Doaa
Azar, Aida Joseph
Khamis, Amar Hassan
Ammar, Abeer
author_sort Adan, Heba
collection PubMed
description BACKGROUND: The use of COVID-19 convalescent plasma (CCP) for the treatment of SARS-CoV-2 infection in pregnancy is intriguing in view of its safety profile in pregnancy and historical precedence of the use of plasma for other viral illnesses. This study aimed to evaluate the use of CCP in pregnant women with early COVID-19 infection. METHODS: This is a retrospective case series study. We have included seven pregnant women admitted with early COVID-19 infection to a tertiary care hospital, Latifa Maternity Hospital in Dubai, United Arab Emirates between 12 February and 04 March 2021 and who consented to receive COVID-19 convalescent plasma as part of their treatment plan. Main outcomes measured were clinical and radiological features, laboratory tests, WHO clinical progression scale pre and post treatment, and maternal, fetal outcomes. COVID-19 clinical severity was classified according to the NIH guidelines for criteria of SARS-CoV-2. For the radiological features, a modified chest X-ray scoring system was used where each lung was divided into 6 zones (3 on each side upper, middle, and lower). Opacities were classified into reticular, ground glass, patchy and dense consolidations patterns. RESULTS: Seven pregnant women with early COVID-19 were enrolled in this study, their mean age was 28 years (SD 3.6). Four had comorbidities: 2 with diabetes, 1 with asthma, and 1 was obese. Five patients were admitted with a WHO clinical progression score of 4 (hospitalized; with no oxygen therapy) and 2 with a score of 5 (hospitalized; oxygen by mask/nasal prongs). Upon follow up on day 10, 6 patients had a WHO score of 1 or 2 (asymptomatic/mild symptoms) indicating clinical recovery. Adverse reactions were reported in 2 patients, one reported a mild skin rash, and another developed transfusion related circulatory overload. All patients were discharged alive. CONCLUSION: CCP seems to be a promising modality of treating COVID-19 infected pregnant women. However, further studies are needed to ascertain the efficacy of CCP in preventing progressive disease in the management of COVID-19 infection in pregnant women.
format Online
Article
Text
id pubmed-9509581
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95095812022-09-26 Use of convalescent plasma in pregnant women with early stage COVID-19 infection in a tertiary care hospital in Dubai, February to March 2021: a case series study Adan, Heba Harb, Deemah Hazari, Komal Abdelkareem, Widad Khan, Fareeda Nikhat Zouaoui, Maryam Raouf, May Elsawy, Doaa Azar, Aida Joseph Khamis, Amar Hassan Ammar, Abeer BMC Pregnancy Childbirth Research BACKGROUND: The use of COVID-19 convalescent plasma (CCP) for the treatment of SARS-CoV-2 infection in pregnancy is intriguing in view of its safety profile in pregnancy and historical precedence of the use of plasma for other viral illnesses. This study aimed to evaluate the use of CCP in pregnant women with early COVID-19 infection. METHODS: This is a retrospective case series study. We have included seven pregnant women admitted with early COVID-19 infection to a tertiary care hospital, Latifa Maternity Hospital in Dubai, United Arab Emirates between 12 February and 04 March 2021 and who consented to receive COVID-19 convalescent plasma as part of their treatment plan. Main outcomes measured were clinical and radiological features, laboratory tests, WHO clinical progression scale pre and post treatment, and maternal, fetal outcomes. COVID-19 clinical severity was classified according to the NIH guidelines for criteria of SARS-CoV-2. For the radiological features, a modified chest X-ray scoring system was used where each lung was divided into 6 zones (3 on each side upper, middle, and lower). Opacities were classified into reticular, ground glass, patchy and dense consolidations patterns. RESULTS: Seven pregnant women with early COVID-19 were enrolled in this study, their mean age was 28 years (SD 3.6). Four had comorbidities: 2 with diabetes, 1 with asthma, and 1 was obese. Five patients were admitted with a WHO clinical progression score of 4 (hospitalized; with no oxygen therapy) and 2 with a score of 5 (hospitalized; oxygen by mask/nasal prongs). Upon follow up on day 10, 6 patients had a WHO score of 1 or 2 (asymptomatic/mild symptoms) indicating clinical recovery. Adverse reactions were reported in 2 patients, one reported a mild skin rash, and another developed transfusion related circulatory overload. All patients were discharged alive. CONCLUSION: CCP seems to be a promising modality of treating COVID-19 infected pregnant women. However, further studies are needed to ascertain the efficacy of CCP in preventing progressive disease in the management of COVID-19 infection in pregnant women. BioMed Central 2022-09-25 /pmc/articles/PMC9509581/ /pubmed/36155102 http://dx.doi.org/10.1186/s12884-022-05043-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Adan, Heba
Harb, Deemah
Hazari, Komal
Abdelkareem, Widad
Khan, Fareeda Nikhat
Zouaoui, Maryam
Raouf, May
Elsawy, Doaa
Azar, Aida Joseph
Khamis, Amar Hassan
Ammar, Abeer
Use of convalescent plasma in pregnant women with early stage COVID-19 infection in a tertiary care hospital in Dubai, February to March 2021: a case series study
title Use of convalescent plasma in pregnant women with early stage COVID-19 infection in a tertiary care hospital in Dubai, February to March 2021: a case series study
title_full Use of convalescent plasma in pregnant women with early stage COVID-19 infection in a tertiary care hospital in Dubai, February to March 2021: a case series study
title_fullStr Use of convalescent plasma in pregnant women with early stage COVID-19 infection in a tertiary care hospital in Dubai, February to March 2021: a case series study
title_full_unstemmed Use of convalescent plasma in pregnant women with early stage COVID-19 infection in a tertiary care hospital in Dubai, February to March 2021: a case series study
title_short Use of convalescent plasma in pregnant women with early stage COVID-19 infection in a tertiary care hospital in Dubai, February to March 2021: a case series study
title_sort use of convalescent plasma in pregnant women with early stage covid-19 infection in a tertiary care hospital in dubai, february to march 2021: a case series study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509581/
https://www.ncbi.nlm.nih.gov/pubmed/36155102
http://dx.doi.org/10.1186/s12884-022-05043-w
work_keys_str_mv AT adanheba useofconvalescentplasmainpregnantwomenwithearlystagecovid19infectioninatertiarycarehospitalindubaifebruarytomarch2021acaseseriesstudy
AT harbdeemah useofconvalescentplasmainpregnantwomenwithearlystagecovid19infectioninatertiarycarehospitalindubaifebruarytomarch2021acaseseriesstudy
AT hazarikomal useofconvalescentplasmainpregnantwomenwithearlystagecovid19infectioninatertiarycarehospitalindubaifebruarytomarch2021acaseseriesstudy
AT abdelkareemwidad useofconvalescentplasmainpregnantwomenwithearlystagecovid19infectioninatertiarycarehospitalindubaifebruarytomarch2021acaseseriesstudy
AT khanfareedanikhat useofconvalescentplasmainpregnantwomenwithearlystagecovid19infectioninatertiarycarehospitalindubaifebruarytomarch2021acaseseriesstudy
AT zouaouimaryam useofconvalescentplasmainpregnantwomenwithearlystagecovid19infectioninatertiarycarehospitalindubaifebruarytomarch2021acaseseriesstudy
AT raoufmay useofconvalescentplasmainpregnantwomenwithearlystagecovid19infectioninatertiarycarehospitalindubaifebruarytomarch2021acaseseriesstudy
AT elsawydoaa useofconvalescentplasmainpregnantwomenwithearlystagecovid19infectioninatertiarycarehospitalindubaifebruarytomarch2021acaseseriesstudy
AT azaraidajoseph useofconvalescentplasmainpregnantwomenwithearlystagecovid19infectioninatertiarycarehospitalindubaifebruarytomarch2021acaseseriesstudy
AT khamisamarhassan useofconvalescentplasmainpregnantwomenwithearlystagecovid19infectioninatertiarycarehospitalindubaifebruarytomarch2021acaseseriesstudy
AT ammarabeer useofconvalescentplasmainpregnantwomenwithearlystagecovid19infectioninatertiarycarehospitalindubaifebruarytomarch2021acaseseriesstudy